NEW YORK, Nov. 21, 2017 /PRNewswire/ -- If you want a Stock Review on ELGX, DXTR, BDX, or EKSO then come over to http://dailystocktracker.com/register/
Irvine, California headquartered Endologix Inc's shares gained 0.38%, closing Monday's trading session at $5.28. The stock recorded a trading volume of 368,397 shares. The Company's shares have advanced 3.53% in the last month and 25.71% over the previous three months. The stock is trading 5.42% above its 50-day moving average. Additionally, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 53.91.
On November 08th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $5 a share to $4 a share.
On November 14th, 2017, Endologix announced that John McDermott, CEO, will present at the Piper Jaffray 29th Annual Healthcare Conference on November 29th, 2017, at 2:50 p.m. ET in New York, NY. A live webcast of the presentation will be accessible under the "Investors" section of the Company's website. See our free and comprehensive research report on ELGX at:
On Monday, shares in Redwood City, California-based Dextera Surgical Inc. recorded a trading volume of 2.03 million shares. The stock dropped 3.12%, ending the day at $0.16. The Company's shares are trading below their 50-day moving average by 32.00%. Furthermore, shares of Dextera Surgical, which designs and manufactures proprietary stapling devices for minimally invasive surgical procedures in the US, Japan, Germany, and internationally, have an RSI of 36.66.
On November 09th, 2017, Dextera Surgical announced financial results for its fiscal Q1 ended September 30th, 2017. Total product sales were approximately $0.6 million for Q1 FY18, total revenue was approximately $0.7 million, total operating costs and expenses were $4.5 million, and net loss was approximately $3.5 million. Cash and cash equivalents were approximately $4.2 million, as of September 30th, 2017. DXTR free research report is just a click away at:
Becton, Dickinson, and Co.
Franklin Lakes, New Jersey headquartered Becton, Dickinson, and Co.'s stock finished the day 0.54% higher at $221.50 with a total trading volume of 807,948 shares. The Company's shares have advanced 4.56% in the last one month, 10.55% in the previous three months, and 33.80% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.79% and 14.27%, respectively. Additionally, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 64.83.
On November 03rd, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $210 a share to $230 a share.
On November 16th, 2017, Becton, Dickinson and Co. announced that it will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics, and expert services at this year's American Society of Health-System Pharmacists 2017 Midyear Meeting to be held from December 03rd, 2017, to December 07th, 2017 in Orlando. Sign up for your complimentary report on BDX at:
Ekso Bionics Holdings
Shares in Richmond, California headquartered Ekso Bionics Holdings Inc. ended yesterday's session 22.18% higher at $2.92. The stock recorded a trading volume of 10.86 million shares, which was above its three months average volume of 1.14 million shares. The Company's shares have skyrocketed 158.41% in the last one month and 108.57% over the previous three months. The stock is trading 132.98% and 38.68% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, Middle-East, and Africa, have an RSI of 84.52.
On November 08th, 2017, Ekso Bionics reported financial results for Q3 ended September 30th, 2017. Revenue for Q3 2017 was $1.6 million, gross profit was $0.5 million, and net loss applicable to common stockholders was $6.3 million. Sales and marketing expenses for the quarter were $3.2 million; R&D expenses were $2.0 million; and G&A expenses were $2.4 million. Register for free on DailyStockTracker.com and download the latest research report on EKSO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. RohitTuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: (207) 331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/breakfast-technical-briefing-on-medical-supplies-stocks----endologix-dextera-surgical-becton-dickinson-and-ekso-bionics-300560076.html
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All